艾滋病的抗病毒治疗版修改201212202.ppt

3TC, lamivudine; ABC, abacavir; ATV, atazanavir; DRV, darunavir; EFV, efavirenz; FPV, fosamprenavir; FTC, emtricitabine; LPV, lopinavir; RTV, ritonavir; SQV, saquinavir; TDF, tenofovir November 3, 2008, updates: DRV/RTV once daily added as preferred PI component Once-daily LPV/RTV moved from alternative to preferred PI component ABC/3TC moved from preferred to alternative NRTI For more information, go online to: /HIV/Conference%20Coverage/Mexico%20City%202008/Tracks/Firstline/Capsules/THAB0303.aspx BID, twice daily; EFV, efavirenz; FTC, emtricitabine; QHS, once daily at bedtime; RAL, raltegravir; TDF, tenofovir. Moving to newer classes of agents, Lennox and colleagues presented 48-week data evaluating the integrase inhibitor raltegravir, which is currently approved for use in treatment-experienced patients only, compared with efavirenz, both in combination with tenofovir/emtricitabine. This study was performed in treatment-naive patients with HIV-1 RNA 5000 copies/mL who had no documented resistance to efavirenz, tenofovir, or emtricitabine. As the study design shows, the primary endpoint was the proportion of participants who achieved HIV-1 RNA 50 copies/mL at Week 48. Secondary study endpoints included increases in CD4+ cell count, safety, and tolerability. More than one half of these patients had baseline HIV-1 RNA 100,000 copies/mL, and nearly one half of patients had CD4+ cell counts 200 cells/mm^3. This is typical of the patient population in whom we are initiating therapy in our clinics today. For more information, go online to: /HIV/Conference%20Coverage/Washington%202008/Tracks/First-Line/Capsules/896a.aspx CI, confidence interval; EFV, efavirenz; ITT, intent to treat; NC = F, noncompleter equals failure; RAL, raltegravir. Using a noncompleter-equals-failure analysis at Week 48, 86% of participants in the raltegravir arm achieved HIV-1 RNA 50 copies/mL compared with 82% of participants in the efavirenz arm. These data established that raltegravir was